Author name: Immunwork Web Team

Immunwork won the 21st National Innovation Award – Enterprise Innovation Award

News /

Immunwork with its “Application of an Innovative Fatty Acid Bundle Platform in the Development of Ultra-Long-Acting Drugs” project, has been honored with the 21st National Innovation Award – Enterprise Innovation Award. This prestigious recognition highlights the excellence of Immunwork’s platform technology and the promising potential drug candidates, earning high acclaim from both national and professional […]

Immunwork won the 21st National Innovation Award – Enterprise Innovation Award Read More »

We will be participating in the 8th Taiwan Healthcare+ Expo Taiwan. Welcome to visit us

Meeting /

The annual Taiwan Healthcare+ Expo will be held from December 5 to 8, 2024, at Hall 1 of the Nangang Exhibition Center. We are honored to be invited to showcase our booth in the InnoZone Innovation Technology Pavilion. You’re welcome to visit us and learn about our latest developments!

We will be participating in the 8th Taiwan Healthcare+ Expo Taiwan. Welcome to visit us Read More »

Join our presentation at the ACCESS CHINA Partnering Forum

Meeting /

Dr. Kun-Po Li, the director of business development of Immunwork, will be presenting at the ACCESS CHINA Partnering Forum – Autumn Virtual Showcase during September 24th to 25th, and 27th, 2024. Dr. Li will unravel the innovations behind our cutting-edge therapeutic peptides and ADC platform, highlighting the distinctive “Multi-Arm Linkers.”

Join our presentation at the ACCESS CHINA Partnering Forum Read More »

Two ultra-long acting drugs receive promising news! Phase 1 clinical trials are expected to be completed next year!

R&D Progress /

Immunwork announced that two ultra-long-acting drugs developed using innovative fatty acid bundles technology platform have received approval from the Australian Human Research Ethics Committee in May. TE-8105 targets obesity (including weight management), type 2 diabetes, and fatty liver disease, while TE-8214 targets neuroendocrine tumors and acromegaly. Both drugs have undergone initial dosing in low-dose subjects,

Two ultra-long acting drugs receive promising news! Phase 1 clinical trials are expected to be completed next year! Read More »

The 2024 Tang Prize is awarded to three scientists for the development of GLP-1

Reported /

The 2024 Tang Prize in Biopharmaceutical Science has cast a spotlight on GLP-1 receptor agonists, sparking a global race among pharmaceutical companies. TE-8105 of Immunwork, an ultra-long-acting GLP-1 drug, is set to initiate its Phase I clinical trial in Australia, promising significant potential for future development! News website link: 1. https://www.chinatimes.com/newspapers/20240624000185-260202?utm_source=iii_news&utm_medium=rss&chdtv 2. https://www.chinatimes.com/newspapers/20240620000187-260202?chdtv

The 2024 Tang Prize is awarded to three scientists for the development of GLP-1 Read More »

Our latest research result is published in Advanced Science

Scientific Publication /

Exciting news! Our latest published paper offers promising solutions for multiple myeloma treatment through ADC technology platform! We are thrilled to announce the publication of our paper “An Antibody-Drug Conjugate for Multiple Myeloma Prepared by Multi-Arm Linkers” in the prestigious Advanced Science journal. Led by Dr. Allen Yueh-Hsiang Yu, our Senior Manager of Preclinical Development

Our latest research result is published in Advanced Science Read More »

Join Our presentation at the prestigious J.P. Morgan Healthcare Conference

Meeting /

Our Chairman, Dr. Tse-Wen Chang and VP of R&D, Dr. Hsing-Mao Chu are honored speakers at the prestigious J.P. Morgan Healthcare Conference on Februry 21-22, 2024.  Dr. Chang and Dr. Chu will share company updates, provide invaluable perspectives, and introduce revolutionary tech platforms and drug candidates. 

Join Our presentation at the prestigious J.P. Morgan Healthcare Conference Read More »

FDA approves Xolair as first and only medicine for children and adults with one or more food allergies

Reported /

Congratulations to our founder, Dr. Tse-Wen Chang, the inventor of Xolair.We are thrilled to learn that Xolair’s potential benefits are extending to more patients, especially those with food allergies. The website link: https://www.businesswire.com/news/home/20240215550080/en/FDA-Approves-Xolair-as-First-and-Only-Medicine-for-Children-and-Adults-With-One-or-More-Food-Allergies

FDA approves Xolair as first and only medicine for children and adults with one or more food allergies Read More »

Scroll to Top